Baccuico has developed a proprietary bacterial cultivation platform that combines directed evolution, next generation sequencing, and machine learning to access novel compounds from biological ‘dark matter’.
The company’s Bacterial Community Cultivation platform (BACCU) directs the evolution of unculturable bacteria, so that the bacteria evolve to become culturable in the lab. Once brought into the laboratory, these bacteria can be screened for valuable metabolites.
Baccuico says that less than 1% of bacteria up until now have been cultured in a laboratory. However using the company’s platform it has been able to boost cultivation rates to around 20%, which has allowed it to start building a library of novel bacterial species for downstream metabolite screening.
The company aims to tackle the antibiotic resistance crisis by discovering novel antibiotic classes targeting some of the most urgent bacterial pathogens, before moving on to broader applications across the medical, agricultural and industrial spaces.
Founded in 2020, Baccuico is based in the UK and is backed angel investors including Jonathan Milner (Founder of Abcam), Lord David Prior (Chairman of the NHS), Peder Holk Neilsen (Former President and CEO of Novozymes), and Leopoldo Zambeletti (Former Head of Healthcare at JP Morgan), among others.
Subscribe for alerts on new companies featured on Startups.Bio
Empyrean Neuroscience has developed a platform for genetically engineering small molecule therapeutics from fungi and plants to treat neuropsychiatric and neurologic disorders. Through precision targeting …
EnPlusOne Biosciences aims to bring a versatile, sustainable, and scalable RNA synthesis technology to market to unlock development of new RNA drugs, vaccines, and gene-editing …
MxT Biotech, a Korea University spin-out, aims to transform cancer immunotherapy, cellular engineering and genome editing with its patented non-viral genome editing technology. The Hydroporator™ …
Vilya is a spin-out of the University of Washington Institute for Protein Design (IPD), with a platform to design membrane-permeable peptides with high structural accuracy, …
Biotechnology is in the midst of a exciting era of innovation, with an ever-expanding toolbox of modalities and approaches spawning development of exciting new vaccines, …
